Last 47 quarters of trend data · Consumer Defensive · Packaged Foods
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has compressed 80.1% YoY to 1.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 32.55 | — | — | 14.97 | 14.17 | 39.01 | 16.93 | 20.94 | 14.10 | 15.40 | 24.83 | 17.71 | 16.55 |
| — | — | — | -28.5% | +0.5% | +153.3% | -31.8% | +18.3% | -14.8% | -23.6% | +38.2% | -5.6% | -4.0% | |
| P/S Ratio | 0.38 | 0.39 | 0.61 | 0.61 | 0.53 | 0.80 | 0.90 | 1.02 | 1.03 | 1.17 | 1.33 | 1.29 | 1.22 |
| — | -51.0% | -32.4% | -39.9% | -48.3% | -31.2% | -32.1% | -20.8% | -16.0% | +3.8% | +15.0% | -5.8% | -13.6% | |
| P/B Ratio | 0.60 | 0.61 | 0.90 | 0.99 | 0.91 | 1.17 | 1.36 | 1.69 | 1.87 | 2.08 | 2.41 | 2.61 | 2.67 |
| — | -48.1% | -33.9% | -41.8% | -51.5% | -43.7% | -43.8% | -35.2% | -29.9% | -12.0% | -8.0% | -26.9% | -32.6% | |
| P/FCF | 40.87 | — | — | 20.06 | 10.45 | 43.04 | 6.67 | 40.74 | 16.16 | 13.80 | 13.66 | 51.53 | 28.34 |
| — | — | — | -50.8% | -35.3% | +211.9% | -51.2% | -20.9% | -43.0% | +100.2% | +29.3% | +83.7% | +31.4% | |
| EV / EBITDA | 2.25 | 1.92 | 8.72 | 4.04 | 3.60 | 9.63 | 4.24 | 5.67 | 5.12 | 6.14 | 9.10 | 7.82 | 7.17 |
| — | -80.1% | +105.8% | -28.7% | -29.6% | +56.8% | -53.4% | -27.5% | -28.7% | -8.9% | +22.7% | -11.0% | -15.8% | |
| EV / EBIT | 4.01 | 12.29 | 51.08 | 5.58 | 5.45 | 12.86 | 4.81 | 7.49 | 5.61 | 6.68 | 10.07 | 8.61 | 8.06 |
| — | -4.4% | +962.6% | -25.5% | -2.9% | +92.6% | -52.2% | -13.0% | -30.5% | -18.7% | +12.5% | -16.6% | -18.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
USANA Health Sciences, Inc.'s operating margin was 7.6% in Q4 2025, up 7.1 pp QoQ and up 3.8 pp YoY. The trailing four-quarter average of 5.4% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.3% | 78.2% | 77.2% | 75.4% | 75.6% | 80.1% | 78.6% | 79.3% | 79.7% | 79.5% | 78.5% | 80.5% | 79.1% |
| — | -2.4% | -1.9% | -4.8% | -5.1% | +0.7% | +0.1% | -1.5% | +0.7% | +1.7% | -0.0% | +0.6% | -1.0% | |
| Operating Margin | 5.5% | 7.6% | 0.6% | 7.1% | 6.3% | 3.8% | 7.8% | 8.4% | 10.8% | 11.0% | 8.3% | 10.2% | 10.8% |
| — | +98.4% | -92.6% | -15.4% | -42.0% | -64.9% | -5.6% | -18.2% | +0.2% | +10.7% | -14.9% | -7.7% | -10.8% | |
| Net Margin | 1.2% | -0.8% | -3.1% | 4.1% | 3.8% | 2.1% | 5.3% | 4.9% | 7.3% | 7.6% | 5.3% | 7.3% | 7.4% |
| — | -137.4% | -157.6% | -16.5% | -48.1% | -72.3% | -0.4% | -32.5% | -1.9% | +35.1% | -16.9% | +0.2% | -10.1% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 1.8% | -0.3% | -1.1% | 1.7% | 1.6% | 0.8% | 2.0% | 2.1% | 3.3% | 3.5% | 2.4% | 3.7% | 4.1% |
| — | -137.9% | -155.1% | -19.9% | -51.6% | -76.9% | -16.0% | -44.9% | -19.7% | +14.5% | -34.1% | -22.5% | -27.8% | |
| ROA | 1.4% | -0.2% | -0.9% | 1.3% | 1.3% | 0.6% | 1.6% | 1.7% | 2.6% | 2.7% | 1.9% | 2.9% | 3.1% |
| — | -138.2% | -154.8% | -21.2% | -52.0% | -76.8% | -13.6% | -42.2% | -14.3% | +22.4% | -29.7% | -15.5% | -21.7% | |
| ROIC | 8.6% | 2.9% | 0.2% | 2.9% | 2.7% | 2.0% | 6.7% | 7.6% | 10.5% | 10.6% | 8.0% | 11.1% | 12.6% |
| — | +46.4% | -96.9% | -61.6% | -74.3% | -81.0% | -15.5% | -31.9% | -16.7% | +1.4% | -20.9% | -15.1% | -15.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
USANA Health Sciences, Inc.'s Debt/EBITDA ratio is 0.5x — comfortably within a safe range. The current ratio has improved 12.2% YoY to 2.24x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | — | — | 0.04 | 0.07 | — | — | 0.00 | 0.03 | — | — | — |
| — | -64.3% | — | — | +1392.1% | +151.8% | — | — | — | -16.3% | — | — | — | |
| Debt / EBITDA | 0.15 | 0.51 | — | — | 0.89 | 2.78 | — | — | 0.04 | 0.45 | — | — | — |
| — | -81.7% | — | — | +1900.7% | +512.8% | — | — | — | -8.4% | — | — | — | |
| Current Ratio | 2.24 | 2.24 | 2.23 | 2.15 | 2.05 | 2.00 | 3.93 | 4.03 | 3.74 | 3.52 | 3.47 | 3.41 | 3.04 |
| — | +12.2% | -43.4% | -46.6% | -45.2% | -43.1% | +13.3% | +18.5% | +23.0% | +32.6% | +28.0% | +33.0% | +32.0% | |
| Quick Ratio | 1.45 | 1.45 | 1.46 | 1.47 | 1.51 | 1.50 | 3.37 | 3.44 | 3.20 | 3.00 | 2.94 | 2.86 | 2.54 |
| — | -3.7% | -56.7% | -57.3% | -52.7% | -50.0% | +14.9% | +20.2% | +25.7% | +37.3% | +34.9% | +48.2% | +51.0% | |
| Interest Coverage | 50.32 | 34.96 | 37.61 | 73.65 | 41.73 | 81.84 | 380.76 | 349.80 | 522.37 | 184.52 | 478.47 | 624.49 | 920.39 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying USNA stock.
USANA Health Sciences, Inc.'s current P/E is 32.6x. The average P/E over the last 2 quarters is 14.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
USANA Health Sciences, Inc.'s current operating margin is 5.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking USANA Health Sciences, Inc.'s business trajectory between earnings reports.